Zonisamide Capsules Recalled for Manufacturing Deviations
Glenmark Pharmaceuticals is recalling Zonisamide Capsules 50 mg nationwide due to manufacturing deviations. The recall affects approximately 15,936 bottles across multiple lots with expiration dates in May 2022.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall initiated voluntarily by the manufacturer due to manufacturing deviations. The source text does not report any illnesses, injuries, or adverse events; the hazard is related to potential lack of assurance in the manufacturing process rather than a known safety threat. Per the rubric, CGMP deviations without reported harm or Class I status warrant a score of 2 (Moderate).
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Zonisamide Capsules USP 50 mg (NDC 68462-129-01) due to current Good Manufacturing Practice (CGMP) deviations identified during manufacturing. The affected product is distributed nationwide.
Specifically, the recall involves three lots: 29190043, 29190044, and 29190045, all expiring May 31, 2022. Approximately 15,936 bottles are affected. The recall was initiated by the firm on August 27, 2021, and classified as a voluntary, firm-initiated Class II recall by the FDA on September 21, 2021.
Patients currently taking affected doses should consult their healthcare provider before discontinuing use. Healthcare providers and patients should report any adverse events to the FDA's MedWatch program. The recall was terminated on October 4, 2023.
The recalled product
- Product
- ZONISAMIDE (ZONISAMIDE)
- Brand
- ZONISAMIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Hazard
- cgmp-violation
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lots: 29190043 Exp. 05/31/2022
- 29190044 Exp. 05/31/2022
- 29190045 Exp. 05/31/2022
UPCs (3)
- 0368462130018
- 0368462129012
- 0368462128015
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ZONISAMIDE
- ModeratePrescription Anti-Epilepsy Drug Zonisamide Recalled for Manufacturing Deviations
FDA (Drugs) · 2022-05-04
- ModerateZonisamide Anti-Seizure Capsules Recalled Nationwide for Manufacturing Quality Control Issues
FDA (Drugs) · 2022-05-04
- ModerateDrug Recall: Zonisamide Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2022-05-04
- ModerateZonisamide Capsules Recalled by Glenmark Due to CGMP Deviations
FDA (Drugs) · 2021-09-29
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27